MAIA Biotechnology, Inc. MAIA

MAIA Company Overview

MAIA Biotechnology, Inc. is a U.S.-based clinical-stage biotechnology company focused on the development of targeted immunotherapies for cancer. The company operates within the oncology and biopharmaceutical industries, with a strategic emphasis on therapies designed to exploit cancer cell immortality mechanisms linked to telomere biology. MAIA’s lead product candidate is telomere-targeting agent THIO (6-thio-2’-deoxyguanosine), which is being developed primarily for advanced non-small cell lung cancer and other solid tumors. The company’s business model centers on clinical development, intellectual property generation, regulatory advancement, and potential future commercialization or partnering opportunities for oncology therapeutics.

MAIA was founded in 2018 and is headquartered in Chicago, Illinois. Since inception, the company has concentrated on advancing telomere-directed therapies intended to selectively affect telomerase-positive cancer cells while activating anti-tumor immune responses. MAIA became publicly traded on the NYSE American exchange under the ticker “MAIA.” Its positioning in the oncology market is differentiated by its focus on telomere dysfunction and immune activation as a combined therapeutic strategy, an area that remains relatively specialized compared with broader immuno-oncology and targeted therapy markets.